Sonendo, Inc. Reports Second Quarter 2025 Financial Results and Reaffirms Financial Guidance

What is the actual earnings per share (EPS) for Q2 2025 and how does it compare to analyst expectations? What is the revenue growth rate year‑over‑year and quarter‑over‑quarter? Does the company meet or exceed its previously provided guidance for Q2 2025? How does the current cash balance and burn rate affect the runway and need for additional financing? What guidance did the company reaffirm for FY2025, and is it consistent with analyst consensus? How does Sonendo's performance compare to its peer group (e.g., other dental/medical technology companies)? What are the key drivers behind any revenue or margin changes (e.g., product launches, regulatory approvals)? What is the expected impact on the stock price in the short‑term and medium‑term? What potential catalysts or risks could affect future guidance (e.g., FDA approvals, competitive pressure)? Are there any notable changes in operating expenses or R&D spend that could affect future profitability?